UK Markets open in 4 hrs 16 mins

DMS Imaging SA (0RGO.L)

LSE - LSE Delayed price. Currency in EUR
Add to watchlist
0.0310-0.0990 (-76.15%)
At close: 04:06PM GMT

DMS Imaging SA

7 Rue des Chasseurs Ardennais
Liège 4031

Full-time employees

Key executives

NameTitlePayExercisedYear born
Mr. Frank HazevoetsMD, CEO, CFO & DirectorN/AN/A1966
Dr. Vincent Bille Ph.D.Head of Technical OperationsN/AN/AN/A
Attorney M. Grégory NihonCompliance Officer & Gen. Sec.N/AN/AN/A
Mr. François GaryBus. Devel. & Marketing DirectorN/AN/AN/A
Ms. Marie Pierre BeaumontHead of HRN/AN/AN/A
Ms. Béatrice De Vos Bcpm, M.D., Ph.D.Chief Medical Officer7.5kN/AN/A
Mr. Philippe GhemHead of Commercial Operations & LicensingN/AN/AN/A
Mr. Rémy von FrenckellHead of Clinical Devel.N/AN/AN/A
Ms. Martine DraguetHead of Regulatory Affairs & Quality AssuranceN/AN/AN/A
Amounts are as of 31 December 2017, and compensation values are for the last fiscal year ending on that date. Pay includes salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in EUR.


DMS Imaging SA, a biopharmaceutical company, focuses on the research, development, and commercialization of immunotherapy products for the treatment of allergies in Belgium. Its lead product is gp-ASIT+, which is in the Phase III trial for the treatment of grass pollen. The company is also developing hdm-ASIT+ for the treatment of house dust mite allergy; and pnt-ASIT+ for the treatment of peanut allergy. The company was formerly known as ASIT Biotech S.A. and changed its name to DMS Imaging SA in February 2022. DMS Imaging SA was incorporated in 1997 and is based in Liege, Belgium.

Corporate governance

DMS Imaging SA’s ISS governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while 10 indicates higher governance risk.